Protein Science Sheba protein
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Protein Science (2008), 17:633-643. Published by Cold Spring Harbor Laboratory Press. Copyright © 2008 The Protein Society
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Dwyer, J. J.
Right arrow Articles by Delmedico, M. K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dwyer, J. J.
Right arrow Articles by Delmedico, M. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency

John J. Dwyer1, Karen L. Wilson1, Kimberly Martin1, Jennifer E. Seedorff1, Aisha Hasan1, Robyn J. Medinas2, Donna K. Davison2, Michael D. Feese3,4, Hans-Thomas Richter3,5, Hidong Kim3, Thomas J. Matthews2, and Mary K. Delmedico1

1 Trimeris, Inc., Protein Engineering Group, Morrisville, North Carolina 27560, USA
2 Trimeris, Inc., Virology Group, Morrisville, North Carolina 27560, USA
3 deCODE Biostructures, Inc., Bainbridge Island, Washington 98110, USA

(RECEIVED October 25, 2007; FINAL REVISION January 23, 2008; ACCEPTED January 28, 2008)

HIV fusion is mediated by a conformational transition in which the C-terminal region (HR2) of gp41 interacts with the N-terminal region (HR1) to form a six-helix bundle. Peptides derived from the HR1 form a well-characterized, trimeric coiled-coil bundle in the presence of HR2 peptides, but there is little structural information on the isolated HR1 trimer. Using protein design, we have designed synthetic HR1 peptides that form soluble, thermostable HR1 trimers. In vitro binding of HR2 peptides to the engineered trimer suggests that the design strategy has not significantly impacted the ability to form the six-helix bundle. The peptides have enhanced antiviral activity compared to wild type, with up to 30-fold greater potency against certain viral isolates. In vitro passaging was used to generate HR1-resistant virus and the observed resistance mutations map to the HR2 region of gp41, demonstrating that the peptides block the fusion process by binding to the viral HR2 domain. Interestingly, the activity of the HR2 fusion inhibitor, enfuvirtide (ENF), against these resistant viruses is maintained or improved up to fivefold. The 1.5 Å crystal structure of one of these designs has been determined, and we show that the isolated HR1 is very similar to the conformation of the HR1 in the six-helix bundle. These results provide an initial model of the pre-fusogenic state, are attractive starting points for identifying novel fusion inhibitors, and offer new opportunities for developing HIV therapeutics based on HR1 peptides.

Keywords: fusion inhibitor; HIV; gp41; N-peptide; antiviral; coiled coil; protein design


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by The Protein Society.